Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott D Solomon

Showing results (721-730 of 1,211) with videos related to

Pageof 122
Sort By:
JACC. Heart Failure|July 27, 2025
Expanded Definition of Worsening Heart Failure: Impact on Clinical Outcomes and Quality-of-Life AssessmentRichard S Chaudhary, Syed M D Hussain, Yong-Shi Wang, et al.
American Heart Journal|October 11, 2011
Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)John J V McMurray, Hajime Uno, Petr Jarolim, et al.
Circulation|April 2, 2008
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysisScott D Solomon, Janet Wittes, Peter V Finn, et al.
JACC. Heart Failure|October 10, 2024
Race in Heart Failure: A Pooled Participant-Level Analysis of the Global PARADIGM-HF and PARAGON-HF TrialsHenri Lu, Brian L Claggett, Milton Packer, et al.
European Journal of Heart Failure|December 18, 2024
Mortality after high-risk myocardial infarction over the last 20 years: Insights from the VALIANT and PARADISE-MI trialsAlberto Foà, Maria A Pabon, Eugene Braunwald, et al.
Lancet (London, England)|August 30, 2022
SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trialsMuthiah Vaduganathan, Kieran F Docherty, Brian L Claggett, et al.
European Heart Journal|November 8, 2024
Centrally adjudicated vs. investigator-reported outcomes in randomized heart failure trialsSimon Wandel, Akshay S Desai, Chien-Wei Chen, et al.
Circulation. Heart Failure|August 30, 2024
Effect of Dapagliflozin on Accelerometer-Based Measures of Physical Activity in Patients With Heart Failure: An Analysis of the DETERMINE TrialsKieran F Docherty, Ruben Buendia Lopez, Folke Folkvaljon, et al.
European Heart Journal|January 26, 2007
Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and functionMaria Amigoni, Alessandra Meris, Jens Jakob Thune, et al.
JAMA Cardiology|October 3, 2022
Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVERAkshay S Desai, Pardeep S Jhund, Brian L Claggett, et al.
Pageof 122

Showing results (721-730 of 1,211) with videos related to

Sort By:
Pageof 122
JACC. Heart Failure|July 27, 2025
Expanded Definition of Worsening Heart Failure: Impact on Clinical Outcomes and Quality-of-Life AssessmentRichard S Chaudhary, Syed M D Hussain, Yong-Shi Wang, et al.
American Heart Journal|October 11, 2011
Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)John J V McMurray, Hajime Uno, Petr Jarolim, et al.
Circulation|April 2, 2008
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysisScott D Solomon, Janet Wittes, Peter V Finn, et al.
JACC. Heart Failure|October 10, 2024
Race in Heart Failure: A Pooled Participant-Level Analysis of the Global PARADIGM-HF and PARAGON-HF TrialsHenri Lu, Brian L Claggett, Milton Packer, et al.
European Journal of Heart Failure|December 18, 2024
Mortality after high-risk myocardial infarction over the last 20 years: Insights from the VALIANT and PARADISE-MI trialsAlberto Foà, Maria A Pabon, Eugene Braunwald, et al.
Lancet (London, England)|August 30, 2022
SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trialsMuthiah Vaduganathan, Kieran F Docherty, Brian L Claggett, et al.
European Heart Journal|November 8, 2024
Centrally adjudicated vs. investigator-reported outcomes in randomized heart failure trialsSimon Wandel, Akshay S Desai, Chien-Wei Chen, et al.
Circulation. Heart Failure|August 30, 2024
Effect of Dapagliflozin on Accelerometer-Based Measures of Physical Activity in Patients With Heart Failure: An Analysis of the DETERMINE TrialsKieran F Docherty, Ruben Buendia Lopez, Folke Folkvaljon, et al.
European Heart Journal|January 26, 2007
Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and functionMaria Amigoni, Alessandra Meris, Jens Jakob Thune, et al.
JAMA Cardiology|October 3, 2022
Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVERAkshay S Desai, Pardeep S Jhund, Brian L Claggett, et al.
Pageof 122